Central Retinal Vein Occlusion
Learn about Central Retinal Vein Occlusion (CRVO), a retinal vein occlusion impacting central vision. This resource provides information on CRVO diagnosis, clinical documentation for accurate medical coding, and healthcare management. Find details on symptoms, treatment, and prognosis for retinal vein occlusion. Understand the importance of proper coding for CRVO in a healthcare setting.
Blockage of the central retinal vein, leading to retinal swelling and vision loss.
Sudden painless blurred or lost vision, retinal hemorrhages, dilated veins, cotton wool spots.
Ophthalmology or retinal specialist clinic, emergency room for sudden vision loss.
ICD-10 Code Families
Complete code families applicable to H34.819
When to use each related code
| Description | When to use |
|---|---|
| Blockage of central retinal vein | Use CRVO or Central Retinal Vein Occlusion for central vein blockage. Consider laterality. |
| Blockage of branch retinal vein | Use BRVO or Branch Retinal Vein Occlusion when a branch is blocked, not the entire central vein. Note affected quadrant. |
| Ischemic central retinal vein occlusion | Use only when CRVO is confirmed as ischemic (e.g., 10+ cotton wool spots on exam). Specify laterality. |
Best-practice checklist
- ✓Document visual acuity in both eyes.
- ✓Describe funduscopic exam findings (e.g., retinal hemorrhages, optic disc edema).
- ✓Specify if ischemic or non-ischemic CRVO.
- ✓Note presence/absence of macular edema.
- ✓Record any relevant medical history (e.g., hypertension, diabetes).
Common pitfalls to avoid
Missing or incorrect laterality (right, left, bilateral) for CRVO impacts reimbursement and data accuracy. CDI can query for laterality documentation.
Distinguishing between ischemic and non-ischemic CRVO is crucial for accurate coding (H34.81 vs. H34.83) and affects severity reflection.
Coding for coexisting conditions like glaucoma or hypertension with CRVO is essential for accurate risk adjustment and treatment planning. CDI can clarify documentation.
Best-practice tips
- 01Timely ophthalmology referral for CRVO diagnosis (ICD-10 H34.83, ICD-9 362.36)
- 02Document CRVO laterality, acuity, visual field defects for accurate coding
- 03Assess CRVO risk factors: hypertension, diabetes, glaucoma (ICD codes)
- 04Manage CRVO complications: macular edema, neovascularization (proper CDI)
- 05Comply with quality metrics for CRVO: anti-VEGF therapy documentation
Step-by-step checklist
- 1
Confirm sudden, painless vision loss/blurring in one eye.
- 2
Document afferent pupillary defect and visual acuity.
- 3
Funduscopy: Disc swelling, retinal hemorrhages, venous dilation.
- 4
Assess risk factors: hypertension, diabetes, glaucoma, hypercoagulability.
- 5
Consider OCT and fluorescein angiography for ischemia evaluation.
Ready-to-paste narrative
Patient presents with symptoms suggestive of Central Retinal Vein Occlusion (CRVO). Presenting complaint includes sudden painless vision loss or blurred vision in the affected eye. Examination reveals retinal hemorrhages, dilated and tortuous retinal veins, and optic disc edema. Macular edema may be present, contributing to decreased visual acuity. Differential diagnosis includes branch retinal vein occlusion (BRVO), ocular ischemic syndrome, and diabetic retinopathy. Fluorescein angiography (FA) may be performed to confirm the diagnosis of CRVO and assess macular perfusion. Optical coherence tomography (OCT) is utilized to evaluate the presence and extent of macular edema. The patient's medical history was reviewed for risk factors such as hypertension, diabetes mellitus, hyperlipidemia, glaucoma, and cardiovascular disease. Initial treatment plan includes close observation and management of underlying systemic conditions. Intravitreal injections of anti-VEGF agents may be considered for macular edema to improve visual acuity. Patient education regarding the condition, potential complications including neovascular glaucoma, and the importance of follow-up care was provided. The patient will be scheduled for regular ophthalmologic examinations to monitor disease progression and response to treatment. ICD-10 code H34.81, Central retinal vein occlusion, is recorded for this encounter.
Common questions and answers
What are the key differentiating factors in diagnosing central retinal vein occlusion (CRVO) vs. branch retinal vein occlusion (BRVO) in clinical practice?+
Differentiating between CRVO and BRVO hinges on the location and extent of retinal vein obstruction. CRVO involves the central retinal vein, resulting in widespread retinal hemorrhages and venous dilation throughout the retina, often described as 'blood and thunder' fundus appearance. BRVO, on the other hand, affects a branch of the retinal vein, leading to more localized retinal hemorrhage and edema confined to the affected quadrant or sector. Visual acuity in CRVO can range from near-normal to profound loss, while BRVO typically presents with milder visual impairment, correlating with the affected area. Consider implementing a thorough fundus examination, including fluorescein angiography if necessary, to confirm the diagnosis and assess the extent of vascular involvement. Explore how optical coherence tomography (OCT) can further aid in evaluating macular edema and guiding treatment decisions.
How do I effectively manage a patient presenting with ischemic central retinal vein occlusion (CRVO) and neovascularization?+
Managing ischemic CRVO with neovascularization requires prompt and targeted intervention to prevent further vision loss. Ischemic CRVO is characterized by extensive capillary non-perfusion, often leading to neovascular glaucoma, a sight-threatening complication. Treatment focuses on inhibiting the growth of new, abnormal blood vessels (neovascularization) which can cause vitreous hemorrhage, retinal detachment, and elevated intraocular pressure. Anti-VEGF therapy is the cornerstone of management, aiming to reduce vascular endothelial growth factor (VEGF) levels that drive neovascularization. Learn more about the various anti-VEGF agents available and their specific dosing regimens. Additionally, consider implementing panretinal photocoagulation (PRP) to reduce ischemic retinal areas and the production of VEGF. Close monitoring of intraocular pressure and regular follow-up examinations are crucial for optimal management and timely intervention in cases of neovascular glaucoma development.
Beyond anti-VEGF injections, what other treatment strategies should be considered for macular edema secondary to central retinal vein occlusion (CRVO)?+
While anti-VEGF injections are the first-line therapy for macular edema associated with CRVO, other treatment strategies may be considered in specific cases or as adjunctive therapy. Corticosteroids, either delivered intravitreally or via sustained-release implants, can help reduce inflammation and macular edema. However, they carry the risk of increased intraocular pressure and cataract formation, necessitating careful patient selection and monitoring. In some cases, focal laser photocoagulation may be employed to target leaking microaneurysms, though this approach is less commonly used now with the advent of anti-VEGF therapy. Explore how newer treatment modalities, such as sustained-release corticosteroid implants and novel anti-inflammatory agents, are being investigated for managing CRVO-related macular edema. Optimizing systemic risk factors, such as hypertension and diabetes, also plays a crucial role in the long-term management of CRVO.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.